SPRB
Spruce Biosciences, Inc.
There isn't enough reported data to score SPRB yet.
SPRB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
SPRB's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
SPRB PE Valuation
SPRB has no meaningful PE right now: it lost money over the past year.
SPRB Forward outlook
There aren't enough analyst estimates for SPRB to show an outlook.
SPRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$56.56 | +$29.02 |
| Q2 2026 | -$62.63 | +$24.12 |
| Q1 2026 | -$59.45 | +$40.30 |
| Q4 2025 | -$74.51 | +$22.24 |
| Q3 2025 | -$85.58 | -$15.83 |
| Q2 2025 | -$86.75 | -$10.25 |
| Q1 2025 | -$99.75 | -$15.75 |
| Q4 2024 | -$96.75 | -$3.75 |
SPRB is still losing money, but far less than before: $56.56 per share over the past year, against $147.00 at its worst in late 2022.
SPRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $697K | -76% |
| Q3 2024 | $602K | -80% |
| Q2 2024 | $1.6M | -26% |
| Q1 2024 | $2M | +1.9% |
SPRB's revenue has slid since its 2023 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -3454% | -3067 points |
| Q3 2024 | -1563% | -1118 points |
| Q2 2024 | -623% | +22 points |
| Q1 2024 | -631% | +41 points |
| Q4 2023 | -387% | N/A |
| Q3 2023 | -444% | N/A |
| Q2 2023 | -645% | N/A |
| Q1 2023 | -672% | N/A |
SPRB's operating margin was −3454% last quarter, down 3067 points from the same quarter a year ago, near the bottom of its range since 2023.
SPRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$13.8M | -$8.4M |
| Q2 2026 | -$22.3M | -$13.4M |
| Q1 2026 | -$8.7M | +$4M |
| Q4 2025 | -$6.5M | +$14.2M |
| Q2 2025 | -$8.8M | +$2.3M |
| Q1 2025 | -$12.7M | +$2.2M |
| Q4 2024 | -$20.7M | -$9.5M |
| Q1 2024 | -$15M | -$3.2M |
SPRB has burned cash in almost every quarter: −$51M over the past year, against −$48M the year before.
SPRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +390K shares |
| 1 year | +377% | +2.2M shares |
| 3 years | +422% | +2.3M shares |
| 5 years | +809% | +2.5M shares |
SPRB has 3M diluted shares, up 377% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
SPRB Net Leverage
SPRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SPRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 27.3 | Neutral |
SPRB's weekly RSI is 42 (neutral) and its Stochastic is 27 (neutral).
SPRB PE vs Healthcare Sector
SPRB has no meaningful PE right now: it lost money over the past year.
SPRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 4.5% below |
| 20 week MA | $48.4 | 11% below |
| 50 week MA | $58.4 | 27% below |
| 100 week MA | $45.9 | 6.5% below |
| 200 week MA | $86.6 | 50% below |
SPRB is in a downtrend: it's below all five of its weekly moving averages, and 50% below its 200-week average.
SPRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,275.0 | $1,868.3 | +47% |
| 2021 | $1,868.3 | $279.0 | -85% |
| 2022 | $279.0 | $81.0 | -71% |
| 2023 | $81.0 | $219.8 | +171% |
| 2024 | $219.8 | $32.9 | -85% |
| 2025 | $32.9 | $85.7 | +161% |
| 2026 YTD | $85.7 | $42.9 | -50% |
SPRB's yearly returns have swung widely, from +171% in 2023 to −85% in 2021. It's down 50% so far in 2026.